- Amneal announced a voluntary nationwide hospital-level recall of one lot of magnesium sulfate injection after identifying a product mix-up risk involving tranexamic acid.
- The action highlights supply-chain and quality-control requirements that can affect hospital purchasing decisions and competitive positioning in sterile injectable medicines.
- Amneal said the affected lot (AH250162) was distributed to wholesalers and distributors between 12/22/2025 and 2/27/2026.
- The company reported no adverse event reports related to the recall at the time of the announcement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief on March 24, 2026, and is solely responsible for the information contained therein.
Comments